Last reviewed · How we verify
NCT07243847
Recurrence and Prognosis Prediction Model for Gastric Cancer
trial testing surgery and/or chemo in Gastric Cancer (GC) in 5,000 participants. Completed in 1 November 2025.
1 October 2025
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 January 2000 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 November 2025 |
Drugs / interventions tested
- surgery and/or chemo
Conditions studied
- Gastric Cancer (GC) — all drugs for Gastric Cancer (GC) →
Sponsor
Fudan University
Who can join
Eligibility, any sex, with Gastric Cancer (GC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study, utilizing a large-scale multicenter Eastern database, has established a Deep Learning-based predictive model for recurrence following gastric cancer surgery, which demonstrates robust discriminatory power for early recurrence. Furthermore, the individualized recurrence probability generated by this model can predict long-term postoperative prognosis and effectively stratify patients based on risk, thereby guiding personalized treatment choices. This individualized risk probability is also applicable to both adjuvant chemotherapy and neoadjuvant chemotherapy populations, offering valuable support for precision treatment in gastric cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07243847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer (GC)
Currently open trials in the same condition.
- NCT07522320 — Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management · active not recruiting
- NCT07311408 — SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07366528 — Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer · Phase 3 · recruiting
- NCT07313579 — Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer · recruiting
- NCT07217704 — Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. · Phase 3 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07243847 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07243847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing